Bristol-Myers Squibb Co
NYSE:BMY
Bristol-Myers Squibb Co
Revenue
Bristol-Myers Squibb Co
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Revenue
$48.3B
|
CAGR 3-Years
1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
12%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Revenue
$88.8B
|
CAGR 3-Years
4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
|
Pfizer Inc
NYSE:PFE
|
Revenue
$63.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Revenue
$64.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Revenue
$9.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
8%
|
CAGR 10-Years
7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Revenue
$45B
|
CAGR 3-Years
17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
9%
|
|
Bristol-Myers Squibb Co
Revenue Breakdown
Breakdown by Geography
Bristol-Myers Squibb Co
|
Total Revenue:
48.3B
USD
|
|
United States:
34.1B
USD
|
|
International:
13.2B
USD
|
|
Other:
996m
USD
|
Breakdown by Segments
Bristol-Myers Squibb Co
Bristol-Myers Squibb Co
Glance View
Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.
See Also
What is Bristol-Myers Squibb Co's Revenue?
Revenue
48.3B
USD
Based on the financial report for Dec 31, 2024, Bristol-Myers Squibb Co's Revenue amounts to 48.3B USD.
What is Bristol-Myers Squibb Co's Revenue growth rate?
Revenue CAGR 10Y
12%
Over the last year, the Revenue growth was 7%. The average annual Revenue growth rates for Bristol-Myers Squibb Co have been 1% over the past three years , 13% over the past five years , and 12% over the past ten years .
You don't have any saved screeners yet